Published in BMC Psychiatry on July 18, 2008
SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med (2013) 1.18
A MusD retrotransposon insertion in the mouse Slc6a5 gene causes alterations in neuromuscular junction maturation and behavioral phenotypes. PLoS One (2012) 0.79
Integrative approach for inference of gene regulatory networks using lasso-based random featuring and application to psychiatric disorders. BMC Med Genomics (2016) 0.75
Does aberrant membrane transport contribute to poor outcome in adult acute myeloid leukemia? Front Pharmacol (2015) 0.75
Controlling the false discovery rate in behavior genetics research. Behav Brain Res (2001) 21.82
Linkage disequilibrium in the human genome. Nature (2001) 17.24
PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res (1997) 13.48
An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res (2006) 11.60
GOLD--graphical overview of linkage disequilibrium. Bioinformatics (2000) 9.43
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry (2005) 9.23
Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 8.10
A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res (1991) 6.26
Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell (1999) 4.93
Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry (1959) 2.66
Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter. J Biol Chem (1996) 2.03
Cloning and expression of a human neutral amino acid transporter with structural similarity to the glutamate transporter gene family. J Biol Chem (1993) 1.66
The power of genome-wide association studies of complex disease genes: statistical limitations of indirect approaches using SNP markers. J Hum Genet (2001) 1.66
Molecular genetic studies of schizophrenia. Eur J Hum Genet (2006) 1.64
Genetic basis of schizophrenia. Lancet (1995) 1.63
Genome-wide scans of three independent sets of 90 Irish multiplex schizophrenia families and follow-up of selected regions in all families provides evidence for multiple susceptibility genes. Mol Psychiatry (2002) 1.56
The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux. J Neurochem (1999) 1.50
Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology (2002) 1.33
Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry (2001) 1.14
Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia (2005) 1.11
Evidence for a chromosome 2p13-14 schizophrenia susceptibility locus in families from Palau, Micronesia. Mol Psychiatry (1998) 1.02
Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron (1993) 1.02
Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res (2000) 0.93
Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry (2004) 0.90
Neutral amino acid transporter ASCT1 is preferentially expressed in L-Ser-synthetic/storing glial cells in the mouse brain with transient expression in developing capillaries. J Neurosci (2003) 0.90
Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol (2005) 0.86
Characterization of the 5' region of the rat brain glycine transporter GLYT2 gene: identification of a novel isoform. Neurosci Lett (1998) 0.86
Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2007) 0.84
Functional identification of ASCT1 neutral amino acid transporter as the predominant system for the uptake of L-serine in rat neurons in primary culture. Neurosci Res (2004) 0.84
Changes in region- and cell type-specific expression patterns of neutral amino acid transporter 1 (ASCT-1) in the anterior cingulate cortex and hippocampus in schizophrenia, bipolar disorder and major depression. J Neural Transm (Vienna) (2006) 0.84
Association study of polymorphisms in the GluR5 kainate receptor gene (GRIK1) with schizophrenia. Psychiatr Genet (2001) 0.83
Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des (2005) 0.82
Mutation screening of a neutral amino acid transporter, ASCT1, and its potential role in schizophrenia. Psychiatr Genet (2000) 0.78
No association between genetic variants at the GLYT2 gene and bipolar affective disorder and schizophrenia. Psychiatr Genet (2006) 0.78
Ontogeny and localization of the neutral amino acid transporter ASCT1 in rat brain. Brain Res Dev Brain Res (2001) 0.78
Association study of polymorphisms in glycine transporter with schizophrenia. J Neural Transm (Vienna) (2006) 0.77
Exclusion of linkage between schizophrenia and the gene encoding a neutral amino acid glutamate/aspartate transporter, SLC1A5. Am J Med Genet (1997) 0.77
No association between genetic variants at the ASCT1 gene and schizophrenia or bipolar disorder in a German sample. Psychiatr Genet (2006) 0.76
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Alpha-CaMKII deficiency causes immature dentate gyrus, a novel candidate endophenotype of psychiatric disorders. Mol Brain (2008) 2.55
Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem Biophys Res Commun (2006) 2.27
Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science (2013) 2.04
Distorted perception of smell by volatile agents facilitated inhalational induction of anesthesia. Paediatr Anaesth (2005) 2.02
Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet (2004) 1.95
Genome-wide association study of schizophrenia in a Japanese population. Biol Psychiatry (2010) 1.89
Impact of the DISC1 Ser704Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet (2006) 1.82
The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One (2011) 1.81
Proteasome assembly defect due to a proteasome subunit beta type 8 (PSMB8) mutation causes the autoinflammatory disorder, Nakajo-Nishimura syndrome. Proc Natl Acad Sci U S A (2011) 1.80
Acute physical stress elevates mouse period1 mRNA expression in mouse peripheral tissues via a glucocorticoid-responsive element. J Biol Chem (2005) 1.77
Genome-wide association for methamphetamine dependence: convergent results from 2 samples. Arch Gen Psychiatry (2008) 1.72
The serotonin 1A receptor gene confer susceptibility to mood disorders: results from an extended meta-analysis of patients with major depression and bipolar disorder. Eur Arch Psychiatry Clin Neurosci (2012) 1.70
A two-stage case-control association study of the dihydropyrimidinase-like 2 gene (DPYSL2) with schizophrenia in Japanese subjects. J Hum Genet (2010) 1.52
Three susceptible loci associated with primary open-angle glaucoma identified by genome-wide association study in a Japanese population. Proc Natl Acad Sci U S A (2009) 1.51
Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. Clin Neuropharmacol (2010) 1.51
Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int (2010) 1.49
Copy number variation in schizophrenia in the Japanese population. Biol Psychiatry (2009) 1.49
DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One (2011) 1.48
What is a rational antidepressant treatment for major depression in patients with Parkinson's disease? Psychiatry Clin Neurosci (2012) 1.41
Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun (2004) 1.39
Evaluating the state dependency of the Temperament and Character Inventory dimensions in patients with major depression: a methodological contribution. J Affect Disord (2002) 1.38
Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes. J Neurol Neurosurg Psychiatry (2011) 1.32
Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet (2003) 1.29
A variant C178T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci (2005) 1.28
A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A (2008) 1.27
Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol Psychiatry (2004) 1.26
Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol (2012) 1.25
Genome-wide association study implicates NDST3 in schizophrenia and bipolar disorder. Nat Commun (2013) 1.25
Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum Mol Genet (2008) 1.23
Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics (2008) 1.18
Identification of functional polymorphisms in the promoter region of the human PICK1 gene and their association with methamphetamine psychosis. Am J Psychiatry (2007) 1.17
Multiple system degeneration with basophilic inclusions in Japanese ALS patients with FUS mutation. Acta Neuropathol (2009) 1.16
Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol (2013) 1.16
Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS One (2011) 1.15
Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr Res (2010) 1.15
Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res (2012) 1.15
Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol (2012) 1.14
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation (2013) 1.13
Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet (2005) 1.11
The impact of a genome-wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet (2010) 1.11
Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene (2003) 1.11
Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet (2009) 1.11
Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Hum Mol Genet (2012) 1.10
Haplotype-based localization of an alcohol dependence gene to the 5q34 {gamma}-aminobutyric acid type A gene cluster. Arch Gen Psychiatry (2005) 1.10
Mutation screening of the human Clock gene in circadian rhythm sleep disorders. Psychiatry Res (2002) 1.09
Meta-analysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr Res (2009) 1.09
Analysis of cell-type-specific gene expression during mouse spermatogenesis. Biol Reprod (2004) 1.09
Associations between microRNA expression and mesenchymal marker gene expression in glioblastoma. Neuro Oncol (2012) 1.09
Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry (2009) 1.07
Resequencing and association analysis of the KALRN and EPHB1 genes and their contribution to schizophrenia susceptibility. Schizophr Bull (2010) 1.07
CLOCK may predict the response to fluvoxamine treatment in Japanese major depressive disorder patients. Neuromolecular Med (2009) 1.07
A missense variation in human casein kinase I epsilon gene that induces functional alteration and shows an inverse association with circadian rhythm sleep disorders. Neuropsychopharmacology (2004) 1.07
Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan. BMC Psychiatry (2014) 1.06
Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches. Biol Psychiatry (2009) 1.06
Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry (2013) 1.05
Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics (2010) 1.04
Copy number variations of CCL3L1 and long-term prognosis of HIV-1 infection in asymptomatic HIV-infected Japanese with hemophilia. Immunogenetics (2007) 1.03
Association study of clock gene (CLOCK) and schizophrenia and mood disorders in the Japanese population. Eur Arch Psychiatry Clin Neurosci (2009) 1.02
Insufficient sleep impairs driving performance and cognitive function. Neurosci Lett (2009) 1.02
Poor sleep quality impairs cognitive performance in older adults. J Sleep Res (2013) 1.01
Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes (2010) 1.00
Identification and expression profiling of 10 novel spermatid expressed CYPT genes. Mol Reprod Dev (2006) 0.99
[Anti-NMDA receptor antibody encephalitis with recurrent optic neuritis and epilepsy]. Rinsho Shinkeigaku (2010) 0.99
Aqueous-aqueous two-phase systems composed of low molecular weight of polyethylene glycols and dextrans for counter-current chromatographic purification of proteins. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.99
Poly[tris{μ(2)-4-[4-(di-methyl-amino)-phenyl-diazenyl]benzene-sulfonato}tri-dioxane-tri-sodium(I)]. Acta Crystallogr Sect E Struct Rep Online (2008) 0.99
Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci (2014) 0.98
The International Consortium on Lithium Genetics (ConLiGen): an initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology (2010) 0.98
Mitochondrial DNA 3644T-->C mutation associated with bipolar disorder. Genomics (2004) 0.98
Association of insomnia and short sleep duration with atherosclerosis risk in the elderly. Am J Hypertens (2012) 0.98
Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS One (2011) 0.98
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics (2008) 0.97
Concentriols B, C and D, three squalene-type triterpenoids from the ascomycete Daldinia concentrica. Phytochemistry (2002) 0.97